This is a fixed-combination rapid-dissolving tablet (RDT) containing sermorelin, a growth-hormone-releasing hormone (GHRH) analog, and glycine, an amino acid. The combination is studied for its role in GHRH receptor signaling and glycine-mediated pathways associated with sleep and recovery.

This RDT formulation is used in controlled laboratory workflows and in-vitro systems examining GHRH receptor activity, pituitary signaling, growth-hormone release, and glycine-mediated neurochemical mechanisms. It is applied in structured research models characterizing compound activity and downstream pathway interactions.

The combination supports analytical studies and cell-based models involving GHRH receptor agonism, endogenous growth-hormone secretion, glycine signaling, and recovery-, sleep-, and body-composition-related pathways. It is relevant for pathway characterization and assay development focused on endocrine and neurochemical cross-talk within controlled study frameworks.

This combination is suited for researchers and investigators studying GHRH receptor signaling alongside glycine-mediated sleep and recovery mechanisms within controlled study frameworks.